SecBot SecBot
SECBOTREPLAY Home › Report › TSHA

TSHA · Taysha Gene Therapies priced a $200M underwritten public offering of…

Taysha Gene Therapies, Inc. · 8-K filed Jun 25, 2026 at 16:26 ET

At the news

MIXEDIMPACT 5/10

8-K filed Jun 25, 2026 at 16:26 ET

Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at $6.00/share and 833,333 pre-funded warrants at $5.999/warrant, alongside a 30-day underwriter option for up to 5,000,000 additional shares. The offering, closed simultaneously with this 8-K, was executed at a 13.5% discount to the prior day's close of $6.94, raising ~$187.4M in net proceeds (or ~$215.6M if the greenshoe is fully exercised). The company states these funds extend its cash runway into H2 2028. The dilutive transaction offsets the capital-extending benefit, making the net effect neutral with a modest negative bias from the discount.

  • Priced 32,500,001 common shares at $6.00/share and 833,333 pre-funded warrants at $5.999/warrant
  • Public offering price of $6.00 represents a ~13.5% discount to prior close of $6.94
  • Gross proceeds of ~$200.0M; estimated net proceeds of ~$187.4M (or ~$215.6M if greenshoe fully exercised)
  • Underwriters granted 30-day option to purchase up to 5,000,000 additional shares

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access